Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenezumab (MABT5102A) in mild to moderate Alzheimer's disease (BLAZE)
NCT01397578Phase 2Completed
- Sponsor
- Genentech
- Start
- Aug 2011
- Primary completion
- Apr 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of crenezumab in Alzheimer's disease (AD), sponsored by Genentech. Started Aug 2011; status: completed.
02
Drugs
crenezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01397578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01397578.